262 related articles for article (PubMed ID: 10375613)
21. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
[TBL] [Abstract][Full Text] [Related]
22. Osteosarcoma in adolescents and young adults: new developments and controversies. The Mayo Clinic studies.
Miser JS; Pritchard DJ; Rock MG; Shives TC; Gilchrist GS; Smithson WA; Arndt CA; Edmonson JH; Schaid DJ
Cancer Treat Res; 1993; 62():333-8. PubMed ID: 8096748
[No Abstract] [Full Text] [Related]
23. Neoadjuvant chemotherapy for osseous malignant fibrous histiocytoma of the extremity: results in 18 cases and comparison with 112 contemporary osteosarcoma patients treated with the same chemotherapy regimen.
Bacci G; Ferrari S; Bertoni F; Mercuri M; Forni C; Sottili S; Gasbarrini A; Tienghi A; Cesari M; Campanacci M
J Chemother; 1997 Aug; 9(4):293-9. PubMed ID: 9269611
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy for patients with osteosarcoma: University of Florida studies.
Graham-Pole J; Ayass M; Cassano W; Dickson N; Enneking W; Heare M; Heare T; Marcus R; Saleh R; Spanier S
Cancer Treat Res; 1993; 62():339-46. PubMed ID: 8096749
[No Abstract] [Full Text] [Related]
25. Long-term survivals of stage IIb osteosarcoma: a 20-year experience in a single institution.
Cho Y; Jung GH; Chung SH; Kim JY; Choi Y; Kim JD
Clin Orthop Surg; 2011 Mar; 3(1):48-54. PubMed ID: 21369478
[TBL] [Abstract][Full Text] [Related]
26. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute.
Ferrari S; Bertoni F; Mercuri M; Picci P; Giacomini S; Longhi A; Bacci G
Ann Oncol; 2001 Aug; 12(8):1145-50. PubMed ID: 11583198
[TBL] [Abstract][Full Text] [Related]
27. The multi-institutional osteosarcoma study: an update.
Link MP
Cancer Treat Res; 1993; 62():261-7. PubMed ID: 7682087
[No Abstract] [Full Text] [Related]
28. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin.
Bacci G; Ferrari S; Delepine N; Bertoni F; Picci P; Mercuri M; Bacchini P; Brach del Prever A; Tienghi A; Comandone A; Campanacci M
J Clin Oncol; 1998 Feb; 16(2):658-63. PubMed ID: 9469355
[TBL] [Abstract][Full Text] [Related]
29. A monocentric therapy study: an approach to optimize the results of the treatment of osteosarcoma by protocols based upon HDMTX, associated with systematic conservative surgery.
Delepine N; Delepine G; Desbois JC
Cancer Treat Res; 1993; 62():327-32. PubMed ID: 7682092
[No Abstract] [Full Text] [Related]
30. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: excellent response of the primary tumor to preoperative treatment with methotrexate, cisplatin, adriamycin, and ifosfamide. Preliminary results.
Bacci G; Picci P; Ferrari S; Sangiorgi L; Mercuri M; Bertoni F; Brach del Prever A; Tienghi A; Mancini A; Comandone A
Chir Organi Mov; 1995; 80(1):1-10. PubMed ID: 7641534
[TBL] [Abstract][Full Text] [Related]
32. Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma.
Tsuda Y; Tsoi K; Parry MC; Stevenson JD; Fujiwara T; Sumathi V; Jeys LM
Bone Joint J; 2020 Jun; 102-B(6):795-803. PubMed ID: 32475245
[TBL] [Abstract][Full Text] [Related]
33. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
[TBL] [Abstract][Full Text] [Related]
34. [Preoperative and postoperative chemotherapy of osteogenic sarcoma of the limbs in children].
Muñoz Villa A; Ocete G; Aymerich ML; Maldonado S; Otheo E; Calvo M; Amaya J
Med Clin (Barc); 1996 Jun; 107(5):161-4. PubMed ID: 8758673
[TBL] [Abstract][Full Text] [Related]
35. Histologic Response and Toxicity following Interval-Compressed Four-Drug Therapy Given Preoperatively in Children and Young Adults with Osteosarcoma: A Retrospective Study.
Kang JM; Ju HY; Joo J; Sung JY; Park SY; Kim JH; Kang HG; Kwon M; Park M; Park HJ; Park BK
Oncology; 2020; 98(2):81-90. PubMed ID: 31509843
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.
Kudawara I; Aoki Y; Ueda T; Araki N; Naka N; Nakanishi H; Matsumine A; Ieguchi M; Mori S; Myoui A; Kuratsu S; Hashimoto N; Yoshikawa H
J Chemother; 2013 Feb; 25(1):41-8. PubMed ID: 23433444
[TBL] [Abstract][Full Text] [Related]
37. A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy.
Navid F; Santana VM; Neel M; McCarville MB; Shulkin BL; Wu J; Billups CA; Mao S; Daryani VM; Stewart CF; Kunkel M; Smith W; Ward D; Pappo AS; Bahrami A; Loeb DM; Reikes Willert J; Rao BN; Daw NC
Int J Cancer; 2017 Oct; 141(7):1469-1477. PubMed ID: 28631382
[TBL] [Abstract][Full Text] [Related]
38. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival.
Petrilli AS; de Camargo B; Filho VO; Bruniera P; Brunetto AL; Jesus-Garcia R; Camargo OP; Pena W; Péricles P; Davi A; Prospero JD; Alves MT; Oliveira CR; Macedo CR; Mendes WL; Almeida MT; Borsato ML; dos Santos TM; Ortega J; Consentino E;
J Clin Oncol; 2006 Mar; 24(7):1161-8. PubMed ID: 16505436
[TBL] [Abstract][Full Text] [Related]
39. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.
Bielack SS; Smeland S; Whelan JS; Marina N; Jovic G; Hook JM; Krailo MD; Gebhardt M; Pápai Z; Meyer J; Nadel H; Randall RL; Deffenbaugh C; Nagarajan R; Brennan B; Letson GD; Teot LA; Goorin A; Baumhoer D; Kager L; Werner M; Lau CC; Sundby Hall K; Gelderblom H; Meyers P; Gorlick R; Windhager R; Helmke K; Eriksson M; Hoogerbrugge PM; Schomberg P; Tunn PU; Kühne T; Jürgens H; van den Berg H; Böhling T; Picton S; Renard M; Reichardt P; Gerss J; Butterfass-Bahloul T; Morris C; Hogendoorn PC; Seddon B; Calaminus G; Michelagnoli M; Dhooge C; Sydes MR; Bernstein M;
J Clin Oncol; 2015 Jul; 33(20):2279-87. PubMed ID: 26033801
[TBL] [Abstract][Full Text] [Related]
40. Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy.
Ferrari S; Bacci G; Picci P; Mercuri M; Briccoli A; Pinto D; Gasbarrini A; Tienghi A; Brach del Prever A
Ann Oncol; 1997 Aug; 8(8):765-71. PubMed ID: 9332684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
